Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults

High-dose trivalent inactivated influenza vaccine (HD-IIV3) or recombinant trivalent influenza vaccine (RIV) may increase influenza vaccine effectiveness (VE) in adults with conditions that place them at high risk for influenza complications. This analysis models the public health impact and cost-effectiveness (CE) of these vaccines for 50–64 year-olds. Markov model CE analysis compared 5 strategies in 50–64 year-olds: no vaccination; only...